Biotechnology

Advances in Gene Therapy: The End of the Era of Incurable Genetic Diseases?

Editing an individual’s DNA, to prevent or treat a genetic disease, at one time seemed an impossible task. Remarkably, we are now living in an age of medical development where decades of laboratory research have been successfully translated into gene therapies suitable for human use. Gene therapy may, for example,...

Read more

Big Tech Companies on the Healthcare Market

When you hear about the likes of “Apple”, “Amazon”, “Facebook”, “Google” and Microsoft”, healthcare is not typically the first thing that springs to mind. However, in recent years these tech giants have been emerging in the healthcare sector. What triggered this diversity in their market strategy? How might this affect...

Read more

A Right Pain in the Peripheries? The Supreme Court Decision in Warner-Lambert v Generics & Actavis

Summary In a significant judgment, the UK Supreme Court has rejected Warner-Lambert’s appeal against the revocation of patent EP(UK) No. 0934061, for the use of pregabalin in the treatment of pain. A key part of the ruling was the upholding of the appeal decision that a higher threshold of plausibility...

Read more

In a new age of personalised cancer therapy, is patent law in Europe still fit for purpose?

In the last week it has been announced that the NHS has struck a deal with Novartis to offer their ground-breaking new CAR-T therapy, Kymriah®, to paediatric patients with B cell acute lymphoblastic leukaemia. This is a significant development and means that some patients will now have access to this...

Read more

Asking the right questions to optimise life sciences IP

This article was originally published on Biotech and Money. Supporting commercial goals by asking ‘why?’ As there is no one-size-fits-all approach to developing an effective IP strategy, GJE ensures it has a thorough understanding of its clients’ objectives and developments within their businesses so that it is able to offer the...

Read more